This is a preprint.
Frailty trajectories preceding dementia: an individual-level analysis of four cohort studies in the United States and United Kingdom
- PMID: 38746437
- PMCID: PMC11092835
- DOI: 10.21203/rs.3.rs-4314795/v1
Frailty trajectories preceding dementia: an individual-level analysis of four cohort studies in the United States and United Kingdom
Update in
-
Frailty Trajectories Preceding Dementia in the US and UK.JAMA Neurol. 2025 Jan 1;82(1):61-71. doi: 10.1001/jamaneurol.2024.3774. JAMA Neurol. 2025. PMID: 39527039 Free PMC article.
Abstract
Frailty may represent a modifiable risk factor for dementia, but the direction of that association remains uncertain. We investigated frailty trajectories in the years preceding dementia onset using data from 23,672 participants (242,760 person-years of follow-up, 2,906 cases of incident dementia) across four cohort studies in the United States and United Kingdom. Bayesian non-linear models revealed accelerations in frailty trajectories 4-9 years before incident dementia. Among participants whose time between frailty measurement and incident dementia exceeded that prodromal period, frailty remained positively associated with dementia risk (adjusted hazard ratios ranged from 1.20 [95% confidence interval, CI = 1.15-1.26] to 1.43 [95% CI = 1.14-1.81]). This observational evidence suggests that frailty increases dementia risk independently of any reverse causality. These findings indicate that frailty measurements can be used to identify high-risk population groups for preferential enrolment into clinical trials for dementia prevention and treatment. Frailty itself may represent a useful upstream target for behavioural and societal approaches to dementia prevention.
Conflict of interest statement
Conflict of Interest Statement DW, JR, TL, IF, MC, LW, EG, DL, JR, RH and ES have nothing to report. KR reports grants from Nova Scotia Health Research Fund, during the conduct of the study; personal fees from Ardea Outcomes, the Chinese Medical Association, Wake Forest University Medical School Centre, the University of Nebraska - Omaha, the Australia New Zealand Society of Geriatric Medicine, the Atria Institute, Fraser Health Authority, Fraser Health Authority, McMaster University, and EpiPharma Inc, outside the submitted work; In addition, Dr. Rockwood has licensed the Clinical Frailty Scale (CFS) to Enanta Pharmaceuticals, Inc, Synairgen Research Ltd, Faraday Pharmaceuticals, Inc., KCR S.A., Icosavax, Inc, BioAge Labs Inc, Biotest AG, Qu Biologics Inc, AstraZeneca UK Litd, Cellcolabs AB, Pfizer Inc, W.L. Gore Associates Inc, pending to Cook Research Incorporated and Rebibus Therapeutics Inc; has licensed the Pictorial Fit-Frail Scale (PFFS) to Congenica;,and as part of Ardea Outcomes Inc has a pending patent for Electronic Goal Attainment Scaling. Use of both the CFS and PFFS is free for education, research and non-profit health care with completion of a permission agreement stipulating users will not change, charge for or commercialize the scales. For-profit entities (including pharma) pay a licensing fee, 15% of which is retained by the Dalhousie University Office of Commercialization and Innovation Engagement. The remainder of the license fees are donated to the Dalhousie Medical Research Foundation and the QEII Health Sciences Centre Research Foundation. In addition to academic and hospital appointments, KR is co-founder of Ardea Outcomes (DGI Clinical until 2021), which in the past 3 years has had contracts with pharma and device manufacturers (Danone, Hollister, INmune, Novartis, Takeda) on individualized outcome measurement.
Figures
References
Publication types
Grants and funding
- P30 AG066515/AG/NIA NIH HHS/United States
- P30 AG062421/AG/NIA NIH HHS/United States
- P30 AG066508/AG/NIA NIH HHS/United States
- P30 AG066519/AG/NIA NIH HHS/United States
- P30 AG072973/AG/NIA NIH HHS/United States
- P30 AG066462/AG/NIA NIH HHS/United States
- P30 AG066530/AG/NIA NIH HHS/United States
- P30 AG066509/AG/NIA NIH HHS/United States
- P20 AG068077/AG/NIA NIH HHS/United States
- P30 AG066546/AG/NIA NIH HHS/United States
- P30 AG072972/AG/NIA NIH HHS/United States
- P30 AG072979/AG/NIA NIH HHS/United States
- P20 AG068082/AG/NIA NIH HHS/United States
- P30 AG072975/AG/NIA NIH HHS/United States
- P30 AG066444/AG/NIA NIH HHS/United States
- P30 AG066507/AG/NIA NIH HHS/United States
- P30 AG072946/AG/NIA NIH HHS/United States
- P30 AG066518/AG/NIA NIH HHS/United States
- P20 AG068053/AG/NIA NIH HHS/United States
- U01 AG009740/AG/NIA NIH HHS/United States
- P30 AG066511/AG/NIA NIH HHS/United States
- U24 AG072122/AG/NIA NIH HHS/United States
- P30 AG066512/AG/NIA NIH HHS/United States
- P30 AG072978/AG/NIA NIH HHS/United States
- P30 AG062429/AG/NIA NIH HHS/United States
- P30 AG062422/AG/NIA NIH HHS/United States
- R01 AG079280/AG/NIA NIH HHS/United States
- P30 AG072977/AG/NIA NIH HHS/United States
- P30 AG062677/AG/NIA NIH HHS/United States
- R01 AG017644/AG/NIA NIH HHS/United States
- P20 AG068024/AG/NIA NIH HHS/United States
- P30 AG072958/AG/NIA NIH HHS/United States
- P30 AG062715/AG/NIA NIH HHS/United States
- P30 AG066506/AG/NIA NIH HHS/United States
- P30 AG066468/AG/NIA NIH HHS/United States
- P30 AG072976/AG/NIA NIH HHS/United States
- P30 AG072947/AG/NIA NIH HHS/United States
- P30 AG072931/AG/NIA NIH HHS/United States
- P30 AG066514/AG/NIA NIH HHS/United States
- P30 AG072959/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
